cancer stem cells ͉ oncogene ͉ EMT T he onset and progression of human and murine mammary tumorigenesis is thought to involve the acquisition of new cellular capabilities (1) , with aberrant proliferation characterized by alteration in cell cycle control protein function (2) . The cyclin/CDK (CDK) inhibitor p21 CIP1 functions as a downstream effector of tumor suppressors including p53, BRCA1, WT1, and TGF␤ (3) . In the absence of p21 CIP1 hematopoietic stem cells (HSCs) (4) , proliferation and absolute number increased, suggesting p21 CIP1 governs HSC cycle entry. p21 CIP1 inhibits cellular growth in tissue culture and tumor xenograft formation (3, 5) . PDGF-induced gliomagenesis, and ATM Ϫ/Ϫ and p53 Ϫ/Ϫ -mediated tumorigenesis was reduced in the p21 CIP1 -deficient background, suggesting a tumor promoting function of p21 CIP1 (6) . In contrast, APC mutation and p18 INKC -deficiencydependent tumorigenesis (7), and mammary gland targeted Ha-Ras or c-Myc-induced tumorigenesis, were each enhanced by p21 CIP1 deficiency (8) .
In addition to these previously described hallmarks, recent studies implicate epithelial mesenchymal transition (EMT) and tumor cancer stem cells (or tumor-initiating cells) in tumor progression (2) . Recent studies have suggested self-renewing stem-like cells, exist within tumors known as cancer stem cells or tumor initiating cells (TICs) (9) (10) (11) . Epithelial cells from murine or human mammary glands or tumors contain stem-like cells that express EMT markers, suggesting a link between EMT and the gain of epithelial stem-like properties (12) .
The current studies were conducted to address the following important questions. First, although p21 CIP1 is known to function as a tumor suppressor, the role of p21 CIP1 in regulating mammary tumor-associated EMT in vivo is unknown. Second, although p21
CIP1 was shown to regulate HSCs, the role in cancer stem cells was unknown. Third, although features of stem cells have been identified by epitope markers in human cancers and cell lines, genome-wide analysis of cancer stem cell signatures induced by specific oncogenes in vivo and the role of the tumor suppressor p21 CIP1 in regulating features of stem cells have not been conducted.
Results

Myc and Ras Induce EMT Gene Expression Signatures in Breast Tumors
Which Are Inhibited by p21 CIP1 . In our previous studies, deletion of (Fig. S1B) . Gene expression that is induced with EMT, was induced in both Ha-Rasand c-Myc-induced tumors. Tumors analysis showed 236 genes were differentially regulated by p21 CIP1 in the context of c-Myc, and 323 genes were differentially regulated by p21 CIP1 in the Ha-Ras tumors (Fig. S1C ). Of these p21 CIP1 regulated genes, 20 genes were common to Ha-Ras and c-Myc.
Genetic Pathways Governing EMT and Stem Cell Quiescence and Self-Renewal Are Repressed by Endogenous p21 CIP1 in OncogeneInduced Mammary Tumors of Transgenic Mice. We used ASSESS for the molecular classification of p21 CIP1 -dependant gene expression sets (14) . In the context of Ras, deletion of p21 CIP1 -induced EMT pathways and pathways regulating the stem cell population [(HSC-LTHSCs) (HSC-long-term HSCs)] (Fig. S1D ). In the context of c-Myc, p21 CIP1 inhibited features of the known EMT-inducing pathways TGF␤ and NF-B (15, 16) (Fig. S1E) . As with the Ras tumors, p21 CIP1 deletion in c-Myc mammary and B) and enhanced migratory capability ( Fig. S3C ), which was further enhanced by serum addition (Fig. S3C ). MCF10A cells grew with a typical sheet of individual epithelium abutting each other, and on collagen matrix developed a spherical shape (Fig. S3D ). MCF10A cells transduced with an expression vector encoding Twist developed the mesenchymal morphology with a more extended and elongated shape, invaded the collagen and grew as tubular structures (Fig. S3D ). Twist expression reduced the epithelial cell markers E-cadherin and ␤-catenin. Conversely, the mesenchymal markers vimentin and N-cadherin were increased (Fig. S3E) .
Activity of the E-cadherin promoter, a useful surrogate for E-cadherin expression, was repressed by Twist, and mutation of the Twist-binding site abrogated Twist-mediated repression (Fig. S3F) . p21 CIP1 reversed Twist-mediated E-cadherin promoter repression (Fig. S3F ). Twist expression correlated with an approximate 80% reduction in p21 CIP1 abundance (Fig. S3G ) and Twist repressed the p21 CIP1 promoter 60% (Fig. S3H ).
Ha-Ras and c-Myc Induce Features of EMT in Human Breast Cancer Cell
Lines. In MCF10A cells Ha-Ras strongly induced Twist expression while induction by c-Myc was modest (Fig. 1A) . MCF10A-Ras cells, and to a lesser extent MCF10A-c-Myc, showed reduced cell-cell contacts with a more polarized fibroblastoid appearance representing morphological changes associated with EMT (Fig.  1B) . Immunohistochemistry (Fig. 1B) for Twist reflected the Western blot finding (Fig. 1 A) and showed Ha-Ras induced Twist expression with modest induction of Twist by c-Myc. Western blot analysis showed features of EMT in MCF10A-Ras cells with a reduction in E-cadherin and ␤-catenin, and induction of vimentin and fibronectin (Fig. 1C) . c-Myc transduced cells showed some features of EMT with decreased E-cadherin and ␤-catenin, and increased fibronectin and vimentin (Fig. 1C) . Ras-transduced MCF10A cells showed a reduction in E-cadherin and induction of vimentin (Fig. 1D) . The epithelial marker ZO-1 (17) was reduced and the mesenchymal marker N-cadherin was increased by Ha-Ras expression or c-Myc transduction (Fig.  S4A ). Ras increased Twist mRNA abundance approximately 2.5-fold quantitated by RT-PCR. Point mutation of S35 in Ras (V12/35S) abrogates JNK without affecting ERK signaling (18) and remained capable of inducing the Twist promoter, whereas the 37G and 40C mutations, which abolish MAPK and PI3K signaling (18) respectively, were incapable of activating Twist (Fig. 1G) . These studies suggest Ha-Ras induction of Twist involves multiple pathways (PI3K, ERK, and JNK). c-Myc expression induced a modest increase in Twist abundance by Western blot and by immunohistochemical staining (Fig. 1 A and B). Twist promoter activity was only modestly induced by c-Myc (Fig. 1E and Fig. S4B ). Ha-Ras-induced Twist promoter activity (Fig. 1F) and was inhibited in a dose-dependant manner by p21 CIP1 (Fig. S4C ).
p21 CIP1 Inhibits Oncogene-Induced EMT. To determine the functional role of p21 CIP1 in Ras-induced EMT, MCF10A cells were sequentially transduced with Ha-Ras or c-Myc and then transduced with either Twist as an inducer of EMT (Fig. 2 A) or p21 CIP1 (Fig. 2B) . Twist ( Fig. 2 A, lanes 1 vs. 4 ), c-Myc (Fig. 2 A, lanes 3 vs. 6 ), and Ha-Ras enhanced expression of the mesenchymal markers fibronectin and vimentin (Fig. 2 A, lanes 2 vs. 5 ). p21 CIP1 -repressed Ha-Ras induced EMT, reducing expression of the mesenchymal marker fibronectin and vimentin (Fig. 2B, lanes 2 vs. 5, and Fig. 3C ). p21 CIP1 modestly affected features of EMT in the MCF10A-c-Myc cells (Fig. 2B, lanes 3 vs. 6 ). As p21 CIP1 inhibited EMT, and EMT in tumor cells is tightly linked to invasive growth, we determined the role of p21 CIP1 in oncogene-mediated migration. MCF10A-Ras cellular migration across a transwell membrane was significantly increased by expression of Twist and reduced by p21 CIP1 (Fig. 2C ). Twist transduction of MCF10A-c-Myc cells increased migration by approximately 50% (Fig. 2D) . p21 CIP1 inhibited the migration of MCF10A-c-Myc cells by Ͼ90%.
We next determined the role of endogenous p21 CIP1 in Ras-and c-Myc-induced EMT using siRNA. Western blot analysis showed Ras-but not c-Myc-induced EMT was significantly reversed by Twist siRNA (Fig. 3A, lanes 2 vs. 5 ), consistent with a role for Twist in Ras-mediated EMT. Twist siRNA reversed Ras-mediated reduction in epithelial markers (E-cadherin and ␤-catenin) and reversed the Ras-mediated induction of the mesenchymal markers (fibronectin and vimentin). This finding is consistent with the model in which Ras and endogenous Twist function in a similar pathway to induce EMT. p21 CIP1 siRNA promoted the induction of mesenchymal markers induced by Ras (fibronectin and vimentin) (Fig. 3B,  lanes 2 vs. 5, S4 ). siRNA-mediated reduction in Twist reduced, but siRNA-mediated reduction in p21 CIP1 -enhanced, Ras-dependent cellular migration in transwell assays (Fig. 3C ). siRNA to Twist or p21 CIP1 did not significantly affect EMT associated markers ( Fig. 3  A and B) or cellular migration in MCF10A-c-Myc cells (Fig. 3C ).
p21 CIP1 Attenuates an Embryonic Stem Cell-Like Gene Expression
Pattern. Genes that were overexpressed in ES cells (19) were increased in abundance in c-Myc-p21 CIP1Ϫ/Ϫ vs. c-Myc-p21
CIP1ϩ/ϩ . A similar pattern was observed in Ras-p21 CIP1Ϫ/Ϫ vs. Rasp21 CIP1ϩ/ϩ (Fig. 4A) . The ES genes regulated by p21 CIP1 were mainly non-overlapping in the Ras vs. c-Myc mammary tumors. The Sox2 gene was differentially regulated by p21 CIP1 in the presence of c-Myc. Sox2, Oct4, Nanog, and KLF4 govern propagation of ES cells in culture (20) . QT-PCR of mRNA extracted from the MMTV-Myc and MMTV-Ras tumor with either p21 CIP1Ϫ/Ϫ or p21 CIP1ϩ/ϩ genotype confirmed the increased abundance of Sox2 and KLF4 in the Ras-p21 CIP1Ϫ/Ϫ and c-Myc-p21 CIP1Ϫ/Ϫ tumors ( Fig.  4 B and C) (note a decrease in delta Ct levels represents an increase in mRNA abundance).
p21 CIP1 Attenuates Expression of c-Myc-Induced Cancer Stem Cell
Markers. Only a small number of primary breast cancer cells, known as cancer stem cells or TICs, form secondary tumors (21) . TICs form non-adherent mammospheres, similar to normal mammary gland stem cells when cultured under specific conditions in the absence of serum (22, 23) . Twist enhanced mammosphere production of MCF10A cells approximately 2-fold (Fig. 5A ). Ha-Ras or c-Myc transduction of MCF10A enhanced the proportion of mammospheres formed 4-and 2-fold respectively (Fig. 5A) . p21 Ϫ cells from 25 to 3% (Fig. 5B) . The proportion of CD44 ϩ /CD24
Ϫ of MCF10A-c-Myc cells were reduced approximately 7-fold by p21 CIP1 expression (49.5 to 6.6%, Fig. 5B ). The proportion of CD44 ϩ /CD24 Ϫ MCF10A-Ras cells were unaltered by p21 CIP1 which may be due to the already very high levels of p21 CIP1 expression in these cells.
Discussion
The current studies demonstrate p21 CIP1 attenuates features of EMT and breast tumor stem cells in cultured cells and in transgenic mice ( siRNA in MCF10A cells, demonstrated that p21 CIP1 inhibited Ras-mediated EMT. Herein Twist repressed the E-cadherin promoter. p21 CIP1 antagonized Twist-mediated repression of Ecadherin promoter activity, via the E-box binding site. These findings are consistent with recent findings that endogenous Twist maintains p21 CIP1 gene expression and the EMT phenotype at MCF7 cells (25) .
Cancer stem cells possess SC-like traits (26) . The current studies provide several lines of evidence that p21 CIP1 represses features of cancer stem cells in mammary tumors. p21 CIP1 repressed the gene expression signature of HSCs, inhibited mammosphere production, and inhibited cell surface markers representing mammary cancer stem cells. Deletion of p21 CIP1 in both Ras-and c-Myc-mediated mammary tumors increased expression of the LTHSC pathway. In prior studies, deletion of p21 CIP1 increased HSC (4). Self-renewal of primitive HSCs requires p21 CIP1 and was defective in p21 CIP1Ϫ/Ϫ mice, suggesting p21 CIP1 functions as a molecular switch governing HSC cycle entry.
Several recent studies have suggested the molecular circuitry controlling embryonic stem (ES) cells may be active in certain tumors. Some of the key regulators of ES cell identity, Oct4, Sox2, KLF4, and Nanog (27) , are expressed in specific tumors (28, 29) . In this regard genome scale location analysis has been used to identify Oct4, Sox2, and Nanog target genes (27) . Our hierarchical clustering, comparing p21 CIP1 -regulated genes in the mammary tumor with gene sets associated with ES cell identity (19) , demonstrated p21 CIP1 -repressed genes were enriched in ES cells. Gene targets of Sox2, Oct4, and Nanog were enriched among p21 CIP1 target genes. Sox2 and KLF4 expression were increased by QT-PCR within Ras or c-Myc tumors upon deletion of p21 CIP1 (Fig. 4 B and C) . Thus the expression profiles repressed by p21 CIP1 in mammary tumors in vivo overlap with repressed gene expression profiles enriched in ES cells and targets of Sox2/Oct4/Nanog.
Experimental Procedures (see SI Text)
Transgenic Animals. The transgenic mice were described in ref. 8 .
RNA Isolation, Quantitative Real-Time PCR, and Microarray Analysis. Probe synthesis and hybridization were performed as described in ref. 30 . The wild-type mammary gland data set was obtained from Gene Expression Omnibus (GSE3765). Analysis of the arrays was performed using the R statistics package (31) and the limma library (32) 
